[心脏病学视角的评论] - Suppr

[Comment from the cardiologic viewpoint].

作者信息

Lüscher Th F

机构信息

Klinik für Kardiologie, Departement Innere Medizin, Universitätsspital Zürich.

出版信息

Praxis (Bern 1994). 2009 Feb 4;98(3):129-30. doi: 10.1024/1661-8157.98.3.129.

DOI:10.1024/1661-8157.98.3.129

PMID:19180438

Abstract

摘要

相似文献

[Comment from the cardiologic viewpoint].

Praxis (Bern 1994). 2009 Feb 4;98(3):129-30. doi: 10.1024/1661-8157.98.3.129.

[Comment from the lipidologic viewpoint].

Praxis (Bern 1994). 2009 Feb 4;98(3):125-7. doi: 10.1024/1661-8157.98.3.125.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Presse Med. 2006 Feb;35(2 Pt 1):219-29. doi: 10.1016/s0755-4982(06)74557-2.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.

Atheroscler Suppl. 2004 Oct;5(3):115-23. doi: 10.1016/j.atherosclerosissup.2004.08.032.

[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].

MMW Fortschr Med. 2006 Jun 15;148(24):4-5.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.

Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C. doi: 10.1016/s0002-9149(03)00004-3.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Clin Ther. 2004 Sep;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006.

Is rosuvastatin really a more efficient therapeutic option than atorvastatin?

Value Health. 2006 Jul-Aug;9(4):276-7; author reply 277-9. doi: 10.1111/j.1524-4733.2006.00111.x.

From CARDS to AURORA: one disease, two responses.

Hellenic J Cardiol. 2010 May-Jun;51(3):281.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Comment from the cardiologic viewpoint].

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

[Comment from the cardiologic viewpoint].

作者信息

机构信息

出版信息